

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Cancer Treatments Advisory Committee Provisional recommendations 30 April 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac’s website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Alectinib for the treatment of resected, anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer, within the context treatments for malignancy, subject to Special Authority criteria	Medium priority
Durvalumab for the treatment of limited-stage, small cell lung cancer, within the context treatments for malignancy, subject to Special Authority criteria	High priority
Inavolisib for the treatment of HR-positive, HER2-negative, locally advanced or metastatic breast cancer, with a <i>PIK3CA</i> mutation, within the context treatments for malignancy, subject to Special Authority criteria	Medium priority
Ibrutinib for the treatment of mantle cell lymphoma, as an alternative to autologous stem cell transplant, within the context treatments for malignancy, subject to Special Authority criteria	High priority
Blinatumomab for the treatment of B-cell lineage acute lymphoblastic leukaemia (ALL), with no measurable residual disease (MRD-negative), within the context treatments for malignancy, subject to Special Authority criteria	High priority

[More information about the agenda items considered at the recent Cancer Treatments Advisory Committee meeting can be found on the Pharmac website.](#)

Released 3 June 2026